Literature DB >> 21586522

Knocking out of CD38 accelerates development of a lupus-like disease in lpr mice.

Marta S Viegas1, Teresa Silva, Maria M Monteiro, Anália do Carmo, Teresa C Martins.   

Abstract

OBJECTIVES: CD38 participates in lymphocyte ontogeny and function and may be involved in autoimmunity. Absence of CD38 accelerates development of non-obese diabetic (NOD) mice diabetes and anti-CD38 antibodies are good markers of human disease. Little is known regarding systemic autoimmunity. Active SLE patients have higher numbers of CD38(+) T and B cells. CD38 is a candidate gene for the murine Lmb2 lupus locus. We aimed to investigate whether CD38 was involved in lupus development.
METHODS: We developed Cd38(-/-)-Fas(lpr)/Fas(lpr) mice and monitored them for development of a lupus-like disease through measurement of protein excretion in urine, histological assessment of the kidneys, quantification of circulating immunoglobulins and autoantibodies. We have also immunophenotyped 2- and 6-month old Cd38(-/-)-Fas(lpr)/Fas(lpr) mice.
RESULTS: We found that absence of CD38 accelerated disease development: female Cd38(-/-)-Fas(lpr)/Fas(lpr) mice presented severe proteinuria, GN, deposition of ICs in the renal medulla and increased amounts of circulating immunoglobulin G (IgG), although anti-dsDNA autoantibodies and RF were not significantly increased at disease onset. We have found that Cd38(-/-)-Fas(lpr)/Fas(lpr) male mice, similarly to other murine models of lupus, were able to control disease. Absence of CD38 in lpr mice altered differentiation of T cells and dendritic cells (DC).
CONCLUSION: Although the role of CD38 in tolerance is still to be elucidated, we provide evidence that it may play an active role in the control of a murine lupus-like disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21586522     DOI: 10.1093/rheumatology/ker178

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

1.  CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus.

Authors:  Ana Henriques; Isabel Silva; Luís Inês; M Margarida Souto-Carneiro; M Luísa Pais; Hélder Trindade; José António Pereira da Silva; Artur Paiva
Journal:  Clin Exp Med       Date:  2015-04-18       Impact factor: 3.984

Review 2.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

3.  CD38 promotes pristane-induced chronic inflammation and increases susceptibility to experimental lupus by an apoptosis-driven and TRPM2-dependent mechanism.

Authors:  Sonia García-Rodríguez; Antonio Rosal-Vela; Davide Botta; Luz M Cumba Garcia; Esther Zumaquero; Verónica Prados-Maniviesa; Daniela Cerezo-Wallis; Nicola Lo Buono; José-Ángel Robles-Guirado; Salvador Guerrero; Elena González-Paredes; Eduardo Andrés-León; Ángel Corbí; Matthias Mack; Friedrich Koch-Nolte; Ramón Merino; Mercedes Zubiaur; Frances E Lund; Jaime Sancho
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

Review 4.  Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.

Authors:  Colton J Garelli; Maggi Ahmed Refat; Padma P Nanaware; Zaida G Ramirez-Ortiz; Mehdi Rashighi; Jillian M Richmond
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

5.  The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections.

Authors:  Eri Katsuyama; Abel Suarez-Fueyo; Sean J Bradley; Masayuki Mizui; Ana V Marin; Lama Mulki; Suzanne Krishfield; Fabio Malavasi; Joon Yoon; Shannan J Ho Sui; Vasileios C Kyttaris; George C Tsokos
Journal:  Cell Rep       Date:  2020-01-07       Impact factor: 9.423

Review 6.  CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity.

Authors:  Zayda L Piedra-Quintero; Zachary Wilson; Porfirio Nava; Mireia Guerau-de-Arellano
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

7.  CD38 Correlates with an Immunosuppressive Treg Phenotype in Lupus-Prone Mice.

Authors:  Jocelyn C Pérez-Lara; Enrique Espinosa; Leopoldo Santos-Argumedo; Héctor Romero-Ramírez; Gabriela López-Herrera; Fabio García-García; Claudia Sandoval-Montes; Vianney Ortiz-Navarrete; Mónica Flores-Muñoz; Juan C Rodríguez-Alba
Journal:  Int J Mol Sci       Date:  2021-11-05       Impact factor: 5.923

8.  CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions.

Authors:  Stephanie A Amici; Nicholas A Young; Janiret Narvaez-Miranda; Kyle A Jablonski; Jesus Arcos; Lucia Rosas; Tracey L Papenfuss; Jordi B Torrelles; Wael N Jarjour; Mireia Guerau-de-Arellano
Journal:  Front Immunol       Date:  2018-07-10       Impact factor: 7.561

9.  Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells.

Authors:  Karsten Lücke; Isabell Yan; Sonja Krohn; Annika Volmari; Stefanie Klinge; Joanna Schmid; Valéa Schumacher; Oliver M Steinmetz; Stefan Rose-John; Hans-Willi Mittrücker
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

10.  CD38 Deficiency Ameliorates Chronic Graft-Versus-Host Disease Murine Lupus via a B-Cell-Dependent Mechanism.

Authors:  África Martínez-Blanco; Marilú Domínguez-Pantoja; María Botía-Sánchez; Sonia Pérez-Cabrera; Nerea Bello-Iglesias; Paula Carrillo-Rodríguez; Natividad Martin-Morales; Antonio Lario-Simón; María M Pérez-Sánchez-Cañete; Laura Montosa-Hidalgo; Salvador Guerrero-Fernández; Victoria M Longobardo-Polanco; Sandra Redondo-Sánchez; Alberto Cornet-Gomez; María Torres-Sáez; Ana Fernández-Ibáñez; Laura Terrón-Camero; Eduardo Andrés-León; Francisco O'Valle; Ramón Merino; Mercedes Zubiaur; Jaime Sancho
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.